Nanotechnology of Inhalable Vaccines for Enhancing Mucosal Immunity: A 2025 Guide

Inhalable vaccines use nanotechnology to deliver antigens directly to the moist surfaces of the respiratory tract, where they trigger a stronger immune response than injected shots. The technology solves a problem that traditional needles cannot address: most pathogens enter the body through mucosal surfaces, yet injected vaccines produce weak protection at those entry points. By packaging vaccine components into particles smaller than a micrometer, researchers can target the lungs and nasal passages directly, activating immune cells that patrol those tissues and produce secretory antibodies.

Why Mucosal Immunity Matters for Respiratory Protection

The immune system has two main branches. Systemic immunity circulates through the blood and lymph, fighting infections that have already entered the body. Mucosal immunity operates at the surfaces where the outside world meets internal tissues — the nose, throat, lungs, gut, and urogenital tract. These surfaces are the first line of defense against airborne viruses, bacteria, and fungi.

Injected vaccines generate high levels of IgG antibodies in the bloodstream. But they produce very little secretory IgA (sIgA), the antibody type that patrols mucosal surfaces. A person with strong systemic immunity can still become infected at the mucosal surface and transmit the pathogen to others. This is why people vaccinated against influenza or COVID-19 can still catch and spread the virus, though they are less likely to become severely ill.

The World Health Organization has identified mucosal immunity as a priority for next-generation vaccines, particularly for respiratory diseases. Delivering vaccine antigens directly to the respiratory mucosa through inhalation can induce both systemic IgG and mucosal sIgA, providing a more complete barrier against infection and transmission.

How Nanotechnology Enables Inhalable Vaccine Delivery

The human lung is a challenging environment for drug delivery. The airways are lined with mucus that traps particles and cilia that sweep them upward to be swallowed or coughed out. Particles must be small enough to bypass these mechanical defenses and reach the deep lung, where immune cells called dendritic cells reside.

Nanotechnology solves this problem through particle engineering. Vaccine components — antigens, adjuvants, and sometimes genetic material — are encapsulated or adsorbed onto particles ranging from about 50 nanometers to 1 micrometer in diameter. At this scale, particles can evade mucociliary clearance, penetrate the mucus layer, and be taken up by antigen-presenting cells.

Several nanocarrier systems are under investigation:

• Lipid nanoparticles: Spherical shells of fatty molecules that can carry mRNA or protein antigens. These are the same technology used in some COVID-19 vaccines, reformulated for aerosol delivery.
• Polymeric nanoparticles: Biodegradable particles made from materials like poly(lactic-co-glycolic acid) (PLGA) or chitosan. They can release antigens slowly over days or weeks, mimicking a natural infection.
• Virus-like particles: Non-infectious shells of viral proteins that resemble a virus but carry no genetic material. They are taken up efficiently by immune cells because they look like a threat.
• Nanogels: Crosslinked polymer networks that swell when they absorb water, releasing their cargo in response to pH or enzyme changes in the respiratory tract.

Each system has different strengths in terms of stability, antigen protection, and immune stimulation. The choice depends on the vaccine target, the desired immune response, and the manufacturing scalability.

Mechanisms of Mucosal Immune Activation

When an inhalable nanoparticle reaches the lung lining, it encounters several types of immune cells. Alveolar macrophages patrol the air sacs, engulfing particles and presenting pieces of them to other immune cells. Dendritic cells extend processes into the airway lumen to sample antigens directly. M cells in the nasal-associated lymphoid tissue transport particles across the epithelial barrier to immune cells waiting below.

Nanoparticles can be designed to target these cells specifically. Surface modifications — such as coating particles with ligands that bind to receptors on dendritic cells — increase uptake efficiency. Once inside the cell, the nanoparticle releases its antigen cargo, which is processed and presented to T cells.

The key outcome is the activation of B cells that produce sIgA. These B cells migrate to the mucosal surfaces and secrete antibodies that bind to pathogens before they can attach to host cells. At the same time, resident memory T cells remain in the lung tissue, ready to respond quickly to reinfection.

Formulation and Stability Considerations

Inhalable vaccines face unique formulation challenges. The particles must be small enough to reach the deep lung but large enough to carry a meaningful dose of antigen. They must remain stable during aerosolization, which subjects them to shear forces in the nebulizer or dry powder inhaler. They must also survive the environment of the respiratory tract, which contains enzymes and immune factors that can degrade unprotected antigens.

Dry powder formulations offer better stability than liquid suspensions. Particles can be freeze-dried or spray-dried into powders that remain stable at room temperature, eliminating the need for cold chain storage. This is a major advantage for distribution in low-resource settings.

The particle size distribution must be tightly controlled. Particles larger than 5 micrometers tend to deposit in the mouth and throat rather than the lungs. Particles smaller than 100 nanometers may be exhaled before they deposit. The optimal range for deep lung delivery is roughly 1 to 3 micrometers for dry powders and 100 to 500 nanometers for liquid aerosols.

Nebulizers and inhalers must also be designed for the specific formulation. Vibrating mesh nebulizers produce fine droplets with minimal shear, making them suitable for lipid nanoparticles. Dry powder inhalers require powders with good flow properties and consistent dose delivery.

Current Research and Clinical Development

Several inhalable nanovaccines have entered clinical trials. The most advanced candidates target influenza, with some also in development for COVID-19, respiratory syncytial virus (RSV), and tuberculosis.

For influenza, inhalable vaccines using virus-like particles have shown the ability to induce both systemic and mucosal antibody responses in Phase 1 and Phase 2 trials. Some formulations include hemagglutinin and neuraminidase antigens from multiple influenza strains, aiming for broader protection against seasonal and pandemic variants.

For COVID-19, researchers have tested inhalable versions of mRNA lipid nanoparticle vaccines and adenovirus-vectored vaccines. Early data suggest that an inhaled booster dose after injected priming can increase mucosal IgA levels that are not achieved by a second injection. This approach is sometimes called “prime-pull” — the injected dose primes systemic immunity, and the inhaled dose pulls immune cells to the mucosal surface.

Tuberculosis poses a particular challenge because the pathogen infects the lungs directly. Inhaled nanovaccines could deliver antigens and adjuvants to the alveolar macrophages where Mycobacterium tuberculosis resides. Preclinical studies in animal models have shown that nanoparticle-based TB vaccines can reduce bacterial burden in the lungs more effectively than injected vaccines.

Nature has published research on inhalable nanovaccines using self-assembling protein nanoparticles that display multiple copies of an antigen on their surface. These platforms mimic the repetitive structure of viral surfaces, which strongly activates B cells.

Safety and Regulatory Pathways

Inhaled vaccines must meet safety standards that differ from injected vaccines. The respiratory tract is sensitive to irritation, and particles that are too large or too reactive can cause inflammation or damage to lung tissue. Biodegradable materials like PLGA and lipids have established safety profiles in other inhaled products, but each new formulation requires testing for local tolerance.

Regulatory agencies including the FDA and EMA have issued guidance for inhaled drug products, but no inhalable vaccine has yet received full approval. The pathways are being developed as candidates advance through clinical trials. Key considerations include:

• Particle characterization (size, shape, surface charge)
• Stability during storage and aerosolization
• Dose uniformity across inhaler actuations
• Local immune response and potential for overstimulation
• Clearance of nanoparticles from the lungs

Manufacturing at scale is another hurdle. Producing nanoparticles with consistent properties requires precise control of mixing, drying, and filling processes. Lipid nanoparticles, for example, are formed by rapid mixing of lipids in ethanol with an aqueous buffer, and small changes in flow rate or temperature can alter particle size and encapsulation efficiency.

Key Takeaways

• Inhaled nanovaccines deliver antigens directly to respiratory mucosal surfaces, inducing secretory IgA antibodies that injected vaccines do not produce.
• Nanoparticles between 50 nanometers and 1 micrometer can penetrate mucus, reach deep lung tissue, and be taken up by antigen-presenting cells.
• Multiple nanocarrier platforms are in development, including lipid nanoparticles, polymeric nanoparticles, virus-like particles, and nanogels.
• Clinical trials for influenza, COVID-19, and other respiratory diseases have shown that inhaled formulations can boost mucosal immunity after injected priming.
• Dry powder formulations offer room-temperature stability, reducing cold chain requirements.
• Regulatory pathways for inhalable vaccines are still evolving, with safety testing focused on local lung tolerance and particle characterization.